Lamivudine

證據等級: L5

預測適應症: 5 個

Lamivudine: From HIV/HBV Antiretroviral to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Lamivudine (3TC) is a well-established nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV-1 infection and chronic hepatitis B, though no formal Philippines registration data was captured in this evidence pack. The TxGNN model’s top-ranked prediction is Simian Immunodeficiency Virus (SIV) infection, with a prediction score of 99.93%, supported by 0 clinical trials and 20 publications — all of which are non-human primate animal studies with no direct human clinical application.

⚠️ Critical Note: All 5 predicted indications in this pack are either non-human animal diseases (SIV, FIV), a rare neurological disorder with zero supporting literature, an obsolete disease ontology term, or a mechanistically mismatched target (HCV). None represents a viable human drug repurposing opportunity in its current form.

Quick Overview

Item	Content
Original Indication	HIV-1 infection and chronic hepatitis B (established clinical use; no Philippines regulatory record captured)
Predicted New Indication	Simian immunodeficiency virus infection
TxGNN Prediction Score	99.93%
Evidence Level	L4
Philippines Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Lamivudine is a cytidine analogue NRTI. Although detailed mechanism of action data was not captured in this evidence pack, Lamivudine’s pharmacology is well established: it competitively inhibits HIV-1 reverse transcriptase (RT) and HBV DNA polymerase, acting as a chain terminator after intracellular phosphorylation to its active triphosphate form. Resistance emerges rapidly via the M184V substitution in RT, which is the canonical marker of 3TC resistance.

SIV (simian immunodeficiency virus) is the non-human primate equivalent of HIV, sharing closely homologous RT sequences. This structural similarity fully explains the TxGNN prediction: the M184V resistance mutation has been directly replicated in SIVmac251-infected macaque models under 3TC therapy, confirming that Lamivudine’s mechanism is active against SIV reverse transcriptase. Multiple animal studies further demonstrate that Lamivudine, as part of HAART regimens, suppresses SIV viremia and tissue reservoirs in macaques.

However, this prediction carries no clinical repurposing value for human medicine. SIV is a disease of non-human primates and does not infect or cause disease in humans. The TxGNN model’s high prediction score almost certainly reflects structural proximity between HIV and SIV nodes within the knowledge graph — a biologically accurate relationship, but one without translatable therapeutic significance. The same pattern applies to the second-ranked prediction (feline immunodeficiency virus/FIV), which is similarly a veterinary-only disease. The remaining three predicted indications (a rare neurological disorder with zero evidence, an obsolete ontology term for hyperlipidemia, and chronic HCV — for which Lamivudine has no known direct antiviral mechanism) further confirm that this evidence pack does not identify actionable repurposing targets.

Clinical Trial Evidence

Currently no related clinical trials registered for Lamivudine in simian immunodeficiency virus infection.

Literature Evidence

All 20 retrieved publications are non-human primate animal studies or basic science. None involves human subjects for SIV treatment.

PMID	Year	Type	Journal	Key Findings
19240457	2009	Animal Study	AIDS (London)	ZDV + 3TC + Indinavir post-exposure prophylaxis prevented vaginal SIV transmission in macaques
12021341	2002	Animal/Basic Science	J Virology	M184V RT mutation emerged within 5 weeks in SIVmac251-infected newborn macaques on 3TC therapy — directly mirrors HIV-1 resistance pattern
12502828	2003	Animal/Basic Science	J Virology	Tenofovir selects for M184V reversion in SIV even with concurrent 3TC; evaluated in SIV macaque model
16973590	2006	Animal Study	J Virology	Quadruple ART including 3TC achieved rapid SIV viral decay in cynomolgus macaques; dynamics modelled mathematically
15919889	2005	Animal Study	J Virology	Lamivudine + efavirenz + tenofovir HAART suppressed RT-SHIV plasma viral RNA by >4 log in all 7 treated rhesus macaques
20868521	2010	Animal Study	Retrovirology	Early initiation of HAART (including 3TC) reduced SIV tissue reservoir establishment in macaques; timing-dependent effect
22615988	2012	Animal Study	PLoS One	HAART (including 3TC) impacted SIV infection in male genital tract of macaques; persistent shedding from local reservoirs
14610172	2003	Animal Study	J Virology	Short-term AZT + 3TC + Indinavir HAART initiated 4 h post-SIV exposure altered lymphocyte proliferation kinetics
11689641	2001	Animal Study	J Virology	HAART (with 3TC) reduced SHIV viremia but did not normalize early bone marrow hematopoiesis defect in macaques
15040537	2004	In Vitro	Antiviral Therapy	Comparative susceptibility of HIV-2, SIV (mac251/B670) and SHIV to 16 approved antiretrovirals including Lamivudine; informs PEP guidance

Philippines Market Information

Lamivudine is currently not registered with the Philippines FDA. No authorization records are available in this evidence pack.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	No registered products found	—	—

Safety Considerations

Please refer to the package insert for safety information. Philippines FDA package insert data was not captured in this evidence pack, and all key warning and contraindication fields returned no data.

For reference, clinicians should consult internationally recognized prescribing information (e.g., WHO/US FDA label) which documents known NRTI class effects including lactic acidosis, hepatomegaly with steatosis, and exacerbation of hepatitis B upon discontinuation.

Conclusion and Next Steps

Decision: Hold

Rationale: All five TxGNN-predicted indications for Lamivudine lack viable human repurposing value: the top two are non-human animal diseases (SIV in macaques, FIV in domestic cats), the third has zero supporting clinical or preclinical literature in humans, the fourth uses an obsolete ontology term with no modern disease correlate, and the fifth (chronic HCV) is mechanistically incompatible — Lamivudine targets RT/DNA polymerase, not HCV NS5B RNA polymerase. The prediction pipeline appears to have correctly identified Lamivudine’s strong RT-inhibitory profile but mapped it predominantly to non-human retroviral disease nodes.

To move forward, the following steps are recommended:

Re-examine the full TxGNN prediction output for human-relevant indications that may have ranked below these animal disease predictions (e.g., HIV-associated complications, HBV-related outcomes, LINE-1-driven inflammatory diseases such as Aicardi-Goutières syndrome — where NRTI use has emerging clinical trial support)
Filter non-human disease ontology terms from the TxGNN prediction pipeline output; SIV and FIV nodes should be excluded from human drug repurposing analysis by design
Retrieve Philippines FDA registration data directly from the FDA Philippines official database to confirm whether Lamivudine products are marketed under any approved brand names (Epivir, Zeffix, or fixed-dose combinations such as Combivir, Triumeq, Dovato) which may not have been captured in the current query
Obtain the complete package insert (Philippines or WHO-INN reference label) to populate safety fields currently missing (key warnings, contraindications, DDI profile)
Verify original indication data — the original_indications field is empty, which is a data pipeline gap; Lamivudine has WHO Essential Medicine status for HIV and HBV and should have known approved indications recorded
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.